The Pharmacology of Bimatoprost (Lumigan™)
- 31 May 2001
- journal article
- review article
- Published by Elsevier BV in Survey of Ophthalmology
- Vol. 45, S337-S345
- https://doi.org/10.1016/s0039-6257(01)00224-7
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Comparison of the Ocular Hypotensive Lipid AGN 192024 With TimololAmerican Journal of Ophthalmology, 2001
- Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamicsAmerican Journal of Ophthalmology, 2001
- Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compoundsBritish Journal of Pharmacology, 2000
- Control of pain initiation by endogenous cannabinoidsNature, 1998
- ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevanceBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1998
- Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2Journal of Biological Chemistry, 1997
- Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoidsSurvey of Ophthalmology, 1997
- Chemical Characterization of a Family of Brain Lipids That Induce SleepScience, 1995
- Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human EyesOphthalmology, 1993
- Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid ReceptorScience, 1992